Protean BioDiagnostics adds Ultra-RAPID Molecular Diagnostics to its Path MAPS™ Products for Colon and Lung Cancer

---

Protean BioDiagnostics is thrilled to announce that it has now added same-day molecular testing capability to its CAP CLIA certified molecular laboratories.  These assays include key biomarker assessments that include evaluation of KRAS, BRAF, and EGFR for presence of activating mutations that guide therapeutic assessment. In addition, Protean has added same day micro-satellite instability (MSI) assessments for FFPE tissues. The MSI assay is unique in that normal tissue is not required. MSI positivity can be an important marker for immunotherapy selection. In addition MSI analysis is a tumor agnostic marker, meaning any solid tumor is eligible for testing using MSI as a companion diagnostic for potential immune therapy selection. 

Protean BioDiagnostic’s mission is to accelerate access to precision oncology to all patients regardless of where they may live.

 Contact info@proteanbiodx.com to learn more.